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Sepsis diagnosis remains based largely on clinical
presentation despite significant advances in the
understanding of underlying pathophysiology and
host-pathogen interactions. The systematic review
article by Zonneveld and colleagues in the previous
issue of Critical Care describes another potential avenue
of study for using biomarkers for sepsis diagnosis and
prognostication. Soluble leukocyte adhesion molecules
and their associated sheddase enzymes vary in
detectable levels and activity in patients in relation to
immunologic status, age, and systemic inflammation,
including in the setting of sepsis. Unfortunately, studies
of these molecules as diagnostic or prognostic aids
(or both) in sepsis have thus far been disappointing.
Zonneveld and colleagues propose two potential
avenues to enhance the performance characteristics of
soluble adhesion molecules and their sheddases in
sepsis diagnosis and prognosis: (a) identifying
age-adjusted normal values for soluble leukocyte
adhesion molecules and their sheddases and
(b) investigating simultaneous measurement of both
soluble adhesion molecules and sheddases in
integrated sepsis evaluation schema. This commentary
discusses the proposed solutions of Zonneveld and
colleagues in more detail and outlines additional
considerations that should be addressed in order to
develop robust and valid diagnostic and prognostic
tools for clinicians managing patients with sepsis.* Correspondence: rmcculloh@cmh.edu
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The article by Zonneveld and colleagues [1] in the previ-
ous issue of Critical Care highlights the ongoing chal-
lenge in identifying and treating septic patients. Few
human maladies prove more resistant to modern diag-
nostic and theragnostic techniques than sepsis. Despite
research describing much of the underlying pathophysi-
ology, sepsis remains a diagnosis based primarily on
clinical presentation [2]. Many attempts at identifying
biomarkers that aid in diagnosis or mortality risk estima-
tion have met with limited success [3]. The elusiveness
of reliable biomarkers in sepsis stems partly from the by-
zantine, interdependent immune processes contributing
to the sepsis syndrome. Zonneveld and colleagues review
the complex interplay of one set of processes. Leukocyte
adhesion molecules, and the sheddase enzymes catalyz-
ing the release of their soluble fragments into the blood-
stream, participate in the homeostasis of immune
responses that direct leukocytes to sites of injury, infec-
tion, and/or inflammation. The authors review previous
failed attempts to use soluble adhesion molecules and
sheddases as diagnostic biomarkers. Undaunted by the
litany of failures identified in their review, Zonneveld
and colleagues describe two key avenues of inquiry that
may reveal the usefulness of soluble leukocyte adhesion
molecules and their sheddases in sepsis diagnosis and
prognosis.
Proposed avenues of inquiry
First, the authors posit that understanding the variation
in circulating levels of soluble adhesion molecules and
sheddases by patient age will help better define normal
values in neonatal, pediatric, and adult sepsis. More ac-
curately defining these normal ranges could improve the
diagnostic and prognostic accuracy of these molecules in
sepsis. To support this assertion, the authors review sev-
eral studies describing developmental differences in cir-
culating levels of soluble adhesion molecules and
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other age-related differences in aspects of the immune
system. For example, CD4+ T-cell counts based on pa-
tient age (for example, a Z-score) better predict oppor-
tunistic infection risk in HIV-positive children than
absolute CD4 counts [4,5]. Age-stratified values have
also been suggested for evaluating the use of sepsis bio-
markers in older patients [6].
Second, Zonneveld and colleagues propose that measur-
ing soluble adhesion markers and their sheddases simul-
taneously may provide greater diagnostic and prognostic
capabilities than measuring either category separately.
Their assertion is important because the complex, inter-
related nature of the immunologic response to sepsis most
likely cannot be distilled to a single component. Prognosis
is undoubtedly related to numerous factors, including
biomarker-associated measures of sepsis severity, age,
comorbidities, disease severity (for example, oxygenation,
organism, or etiology of the septic episode), and other fac-
tors contributing to mortality. Evaluation strategies thus
should seek to integrate the contributions of multiple
potentially prognostic elements.
The challenge, therefore, is to develop a research strategy
that provides the infrastructure capable of modeling the
heterogeneity of patient outcomes. The literature reviewed
by Zonneveld and colleagues is woefully inadequate to do
this. Few of the studies report the association of biomarker
changes to outcome, and all are limited by very small sam-
ple sizes. Ideally, researchers need to assemble a large,
multi-center cohort that exquisitely characterizes septic pa-
tient demographics, medical comorbidities, disease sever-
ity, and sepsis-associated biomarkers. The PROGRESS
(Promoting Global Research Excellence in Severe Sepsis)
registry represents an attempt to create such a cohort but
was limited by variation in reporting rates and lack of data
integrity assurance measures [7]. Most importantly, the
ideal registry needs to accurately document patient out-
comes. From such an observational registry, researchers
could build multi-variable models of mortality, in which
the independent prognostic importance of each variable
could be determined, along with any possible interactions.
In other disciplines, such as cardiology or clinical trials,
such multi-variable models have been invaluable in model-
ing the heterogeneity of risk and treatment benefits and
can be used to guide therapy and improve outcomes [8-12].
Accomplishing this goal will require substantial com-
mitment and collaboration among those interested in
building better sepsis prognostic strategies. If, as a sim-
ple rule of thumb, 10 mortality events are required for
each potential predictor variable and 20% of patients
with sepsis die, then for 10 potential predictors (not in-
cluding interactions) to be identified, a minimum of 500
patients with severe sepsis would need to be enrolled to
perform such an analysis, which represents a majoreffort. This commitment is critical, however, to develop-
ing tools and strategies to improve prognostication, in-
corporate evolving insights into sepsis pathophysiology,
and use this information to better tailor therapy and im-
prove outcomes.
Conclusions
We commend Zonneveld and colleagues for their sys-
tematic review of the leukocyte adhesion molecule-
sheddase system in sepsis. Their work highlights the
needs for more sophisticated methods to define progno-
sis and for challenging the research community to be
sensitive to potential age-based interactions. The job for
researchers and policymakers now is to invest in collect-
ing the data from large, multi-site cohorts and to rigor-
ously analyze the information so that better tools for
prognostication can be developed. Once available, these
tools can become foundational for better informing pa-
tients and families about prognosis, improving diagnos-
tic testing, and directing treatments to those who most
benefit.
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